January - 2018

Developing a safe, convenient, disease-modifying treatment for peanut allergy

News

Collaborator of Aravax, the Benaroya Research Institute, receives $5 million National Institute of H

Collaborator of Aravax, the Benaroya Research Institute, receives $5 million National Institute of H

29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute of Health funding to support investigations into the immune mechanisms of PVX108. The research group led by Erik Wambre (PhD) from the Benaroya Research Institute, became a collaborator of the Australian Biotechnology company Aravax in January 2017. The goal of this funding is to accelerate discovery of treatments for peanut allergies thr

Aravax presents encouraging preliminary Phase I safety data at the worlds’ first Gordon Research Con

Aravax presents encouraging preliminary Phase I safety data at the worlds’ first Gordon Research Con

13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the first Phase I clinical trial of its product known as PVX108 at the Gordon Research Conference on Food Allergy at Ventura Beach in California, held from the 7th-12th January 2018. The Gordon Research Conference brought together leading researchers, clinicians, regulatory and industry representatives from around the world who are working towards

Aravax forms Scientific Advisory Board

Aravax forms Scientific Advisory Board

9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food Allergy at Ventura Beach in California. Aravax is delighted to welcome 5 members to the Scientific Advisory Board. Mark Larché, PhD, is Professor of Medicine at McMaster University, Canada. He is also Chair i

Archive